Emergent BioSolutions shares sold off after the Company posted roughly $234 million in quarterly revenue — above its own prior guidance — while also recording a $191.3 million NARCAN impairment. Levi & Korsinsky is investigating potential securities law violations.
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) — A revenue and earnings beat did not stop Emergent BioSolutions (NYSE: EBS) shares from falling sharply after the Company’s second-quarter release, which disclosed a $191.3 million non-cash NARCAN impairment tied to naloxone competition and pricing pressure. Investors who lost money on EBS are encouraged to submit their information now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
The quarter itself came in ahead of the Company’s prior revenue guidance at approximately $234 million, with adjusted EBITDA of roughly $97 million, up sequentially. Within the same results, Emergent recorded the $191.3 million impairment against NARCAN, citing increased competition and pricing pressure in the naloxone category.
Five months earlier, in its February 26, 2026 earnings presentation, the Company had stated: “Maintained market leadership; pricing stabilized.” Levi & Korsinsky is investigating potential securities law violations on behalf of Emergent BioSolutions shareholders.
Shareholders who purchased EBS stock and suffered a loss are encouraged to have their losses reviewed today or call (212) 363-7500.
ABOUT THE FIRM — For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the EBS Investigation
Q: How much did EBS stock drop? A: Shares fell sharply after the Company disclosed a $191.3 million non-cash NARCAN impairment alongside its second-quarter results. Investors who purchased EBS securities and suffered losses may be eligible to seek recovery.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Emergent BioSolutions made materially false or misleading statements regarding NARCAN pricing and competitive conditions, including the February 26, 2026 statement that naloxone pricing had “stabilized,” before the Company disclosed the $191.3 million NARCAN impairment.
Q: Who is eligible to participate in the EBS investigation? A: Investors who purchased EBS stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.
Q: What do EBS investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my EBS shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought EBS and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost. Securities investigations and any resulting actions are generally handled on a contingency basis — no retainer and no out-of-pocket costs.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
